Argitalpenak (63) JOSE MANUEL BAENA CAÑADA argitalpenak

2024

  1. Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality

    Cancers, Vol. 16, Núm. 6

2023

  1. Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence

    Clinical Drug Investigation, Vol. 43, Núm. 9, pp. 691-698

  2. Association between reproductive history, breast cancer subtype, and survival in premenopausal women

    Medicina Clinica

  3. Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  2. Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer

    Medicina Clinica, Vol. 159, Núm. 8, pp. 351-358

  3. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

    Scientific Reports, Vol. 11, Núm. 1

  2. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176

  3. Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, with 1 to 3 Positive Nodes: A Single-Centre Study

    Archives of Breast Cancer, Vol. 8, Núm. 3, pp. 233-242

2020

  1. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213

  2. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

    Scientific Reports, Vol. 10, Núm. 1

  3. Serum phospholipids fatty acids and breast cancer risk by pathological subtype

    Nutrients, Vol. 12, Núm. 10, pp. 1-18

2019

  1. Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "sEXSAT-Q"

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

  2. Experiences with Prescribing Large Quantities of Systemic Anticancer Therapy near Death

    Journal of Palliative Medicine, Vol. 22, Núm. 12, pp. 1515-1521

  3. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

    Scientific Reports, Vol. 9, Núm. 1

  4. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

2018

  1. Adenocarcinoma de páncreas

    Sanidad y Ediciones

  2. Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (Clinical and Translational Oncology, (2018), 20, 7, (862-869), 10.1007/s12094-017-1797-9)

    Clinical and Translational Oncology

  3. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

    Journal of Clinical Oncology, Vol. 36, Núm. 11, pp. 1073-1079